Wellington Management Group LLP Morphic Holding, Inc. Transaction History

Wellington Management Group LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$26.12 - $34.07 $46.8 Million - $61 Million	1,791,462 Added 44.53%	5,814,446 $198 Million
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $107 Million - $162 Million	4,022,984 New	4,022,984 $142 Million
Q4 2023 Feb 12, 2024	BUY	$19.95 - $31.0 $67.4 Million - $105 Million	3,377,310 New	3,377,310 $97.5 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $23.8 Million - $66.4 Million	1,117,985 Added 48.53%	3,421,820 $78.4 Million
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $41.2 Million - $74.6 Million	1,200,911 Added 108.88%	2,303,835 $132 Million
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $7.97 Million - $14.9 Million	-306,589 Reduced 21.75%	1,102,924 $41.5 Million
Q4 2022 Feb 13, 2023	BUY	$24.14 - $30.37 $1.6 Million - $2.02 Million	66,378 Added 4.94%	1,409,513 $37.7 Million
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $8.18 Million - $12.3 Million	-368,074 Reduced 21.51%	1,343,135 $38 Million
Q2 2022 Aug 15, 2022	BUY	$19.74 - $43.01 $25.4 Million - $55.4 Million	1,289,063 Added 305.36%	1,711,209 $37.1 Million
Q1 2022 May 16, 2022	BUY	$36.25 - $52.02 $15.3 Million - $22 Million	422,146 New	422,146 $16.9 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.